Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06672718
PHASE1
A Study of SPY002-091 in Healthy Volunteers
Sponsor: Spyre Therapeutics, Inc.
View on ClinicalTrials.gov
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single- dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-091 in healthy participants.
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY002-091 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2024-11-26
Completion Date
2026-06-22
Last Updated
2025-08-17
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
SPY002-091
Experimental
OTHER
Placebo
Placebo
Locations (1)
Spyre Site 1
Cypress, California, United States